Blueprint Medicines Corporation (BPMC)

NASDAQ: BPMC · IEX Real-Time Price · USD
55.86
+1.58 (2.91%)
Jul 7, 2022 1:19 PM EDT - Market open
2.91%
Market Cap 3.33B
Revenue (ttm) 221.24M
Net Income (ttm) -650.37M
Shares Out 59.57M
EPS (ttm) -11.06
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 125,000
Open 54.26
Previous Close 54.28
Day's Range 54.07 - 56.07
52-Week Range 43.46 - 117.86
Beta 0.96
Analysts Buy
Price Target 97.48 (+74.5%)
Earnings Date Aug 4, 2022

About BPMC

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma. It is also developing GAVRE... [Read more...]

Industry Biotechnology
IPO Date Apr 30, 2015
CEO Jeffrey Albers
Employees 526
Stock Exchange NASDAQ
Ticker Symbol BPMC
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 21 analysts, the average rating for BPMC stock is "Buy." The 12-month stock price forecast is 97.48, which is an increase of 74.51% from the latest price.

Price Target
$97.48
(74.51% upside)
Analyst Consensus: Buy
Stock Forecasts

News

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Blueprint Medicines Corporation -...

NEW YORK , July 5, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Blueprint Medicines Corporation ("Blueprint" or the "Company") (NASDAQ: BPMC). Such investors are ...

Blueprint inks deal with Sixth Street, Royalty Pharma worth up to $1.2 billion

Shares of Blueprint Medicines Corp. BPMC, -2.34% gained 3.3% in premarket trading on Thursday after the company announced a deal with investment firm Sixth Street and Royalty Pharma RPRX, -1.10% , which...

Other symbols: RPRX

Blueprint Medicines Announces Transformative $1.25 Billion Strategic Financing Collaborations with Sixth Street and R...

Strengthens balance sheet with significant non-dilutive, low-cost capital Expands ability to bring the promise of precision therapy to broad patient populations through internal R&D and strategic busine...

Other symbols: RPRX

Blueprint Medicines Appoints Habib Dable to its Board of Directors

CAMBRIDGE, Mass. , June 23, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced the appointment of Habib Dable to its board of directors.

Blueprint Medicines' (BPMC) Ayvakit Aids Growth Amid Rivalry

Blueprint Medicines' (BPMC) lead drug, Ayvakit, approved to treat rare cancer and other rare diseases, has seen strong uptake since approval. However, stiff competition remains a concern.

Blueprint Medicines Reports Continued Progress Toward Goal of Transforming Treatment of Systemic Mastocytosis

-- New analyses showing AYVAKIT® (avapritinib) significantly improved overall survival in advanced SM, when indirectly compared to real-world data for prior standard therapies, to be presented at EHA 20...

Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

CAMBRIDGE, Mass. , June 3, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy...

Why Is Blueprint Medicines (BPMC) Down 11.4% Since Last Earnings Report?

Blueprint Medicines (BPMC) reported earnings 30 days ago. What's next for the stock?

3 Small-Caps That Might Be Acquisition Candidates

Here's why our roundtable thinks OptimizeRx, Affimed and Blueprint Medicines are all buys right now.

Other symbols: AFMDOPRX

Blueprint Medicines (BPMC) Q1 Loss in Line, Revenues Top Mark

Blueprint Medicines' (BPMC) earnings meet estimates while revenue beat the same for the first quarter of 2022. Stock up.

Blueprint Medicines (BPMC) Reports Q1 Loss, Tops Revenue Estimates

Blueprint Medicines (BPMC) delivered earnings and revenue surprises of 0% and 45.15%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Blueprint Medicines Reports First Quarter 2022 Results

-- Achieved $23.8 million in AYVAKIT® (avapritinib) net product revenues, and $62.7 million in total revenues -- -- AYVAKYT® (avapritinib) launch in Germany underway following European Commission approv...

Blueprint Medicines to Report First Quarter 2022 Financial Results on Tuesday, May 3, 2022

CAMBRIDGE, Mass. , April 26, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:30 a.m.

Blueprint Medicines Announces BLU-945 Proof-of-Concept Data Supporting Initiation of Comprehensive Combination Develo...

-- Early dose escalation data show dose-dependent reductions in ctDNA and tumor burden -- -- Generally well-tolerated with most AEs Grade 1 or 2, supporting continued dose escalation -- -- Initiating SY...

7 Biotech Stocks to Buy With Key Catalysts for April

Biotech stocks are very sensitive to some key catalysts such as the FDA decision date, aka PDUFA date, clinical readouts/presentations and Adcom meeting. The month of April will see some companies belon...

Other symbols: ALNYAPTXBMYCHRSHCMTARS

Blueprint Medicines (BPMC) Gets EU Nod for Ayvakyt in SM

The European Commission approves Blueprint Medicines' (BPMC) Ayvakyt for treating adult patients with advanced systemic mastocytosis.

Blueprint Medicines' AYVAKYT® (avapritinib) Receives European Commission Approval for the Treatment of Adults with Ad...

-- AYVAKYT is the first approved therapy in the European Union designed to selectively target the KIT D816V mutation, the primary driver of disease -- -- Advanced Systemic Mastocytosis (AdvSM) is a debi...

Blueprint Medicines (BPMC) Down 9.1% Since Last Earnings Report: Can It Rebound?

Blueprint Medicines (BPMC) reported earnings 30 days ago. What's next for the stock?

Wednesdays With Wedbush: 3 Smid-Cap Biotech Stock Picks

Since the coronavirus pandemic began in early 2020, the FDA's plate has been full with reviews of COVID-19 vaccines and treatments. That has put the approval of many other drugs and therapies on the bac...

Other symbols: ISEESWTX

Blueprint Medicines to Showcase Broad Precision Therapy Pipeline at AACR Annual Meeting 2022

CAMBRIDGE, Mass., March 8, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced plans to present new clinical and preclinical data for multiple programs across its precisi...

Blueprint Medicines and Proteovant Therapeutics Announce Strategic Collaboration to Advance Novel Targeted Protein De...

CAMBRIDGE, Mass., Feb. 28, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) and Proteovant Therapeutics today announced a strategic collaboration to advance novel targeted protein deg...

Blueprint Medicines (BPMC) Q4 Loss Widens, Revenues Top Mark

Blueprint Medicines (BPMC) misses on earnings while revenue beat estimates for the fourth quarter of 2021. Stock down.

Blueprint Medicines (BPMC) Reports Q4 Loss, Tops Revenue Estimates

Blueprint Medicines (BPMC) delivered earnings and revenue surprises of -39.44% and 3.17%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Blueprint Medicines Reports Fourth Quarter and Full Year 2021 Results

CAMBRIDGE, Mass., Feb. 16, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today reported financial results and provided a business update for the fourth quarter and full year ended ...

Blueprint Medicines to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., Feb. 11, 2022 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC) today announced its participation in the following upcoming investor conferences.